“Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant,” BioNTech CEO Ugur Sahin said Tuesday.
(Image credit: David Goldman/AP)
“Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant,” BioNTech CEO Ugur Sahin said Tuesday.
(Image credit: David Goldman/AP)